
ENVB
Enveric Biosciences Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.340
Open
1.340
VWAP
1.29
Vol
82.86K
Mkt Cap
3.24M
Low
1.265
Amount
106.94K
EV/EBITDA(TTM)
--
Total Shares
7.75M
EV
-1.06M
EV/OCF(TTM)
--
P/S(TTM)
--
Enveric Biosciences, Inc. is a biotechnology company. The Company is engaged in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its discovery and development platform, the Psybrary platform, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, the Company seeks to develop a robust intellectual property portfolio of drug candidates. Its lead molecule, EB-003, is a neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. The Company is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing other Psybrary platform drug candidates to third-party licensees and advancing non-competitive market strategies for patient care.
Show More
Valuation Metrics
The current forward P/E ratio for Enveric Biosciences Inc (ENVB.O) is -1.53, compared to its 5-year average forward P/E of -1.48. For a more detailed relative valuation and DCF analysis to assess Enveric Biosciences Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-1.48
Current PE
-1.53
Overvalued PE
0.48
Undervalued PE
-3.43
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
0.07
Current EV/EBITDA
0.15
Overvalued EV/EBITDA
0.32
Undervalued EV/EBITDA
-0.19
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
-11.70%
-2.19M
Operating Profit
FY2025Q1
YoY :
-11.07%
-2.18M
Net Income after Tax
FY2025Q1
YoY :
-86.75%
-1.22
EPS - Diluted
FY2025Q1
YoY :
-100.00%
N/A
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ENVB News & Events
Events Timeline
2025-07-23 (ET)
2025-07-23
08:51:37
Enveric Biosciences receives second notice of allowance from USPTO for EVM401

2025-07-15 (ET)
2025-07-15
09:36:40
Enveric Biosciences announces results of EB-003 preclinical model

2025-06-24 (ET)
2025-06-24
09:22:08
Enveric announces data broadening clinical potential for lead candidate

Sign Up For More Events
Sign Up For More Events
News
9.0
07-23NewsfilterEnveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
3.5
07-20Yahoo FinanceWeekly Roundup on the Cannabis Sector & Psychedelic Sector
9.0
07-15NewsfilterEnveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)
Sign Up For More News
People Also Watch

INM
InMed Pharmaceuticals Inc
2.640
USD
-1.49%

ASTI
Ascent Solar Technologies Inc
1.690
USD
-5.59%

NIVF
NewGenIvf Group Ltd
0.520
USD
-5.11%

OST
Ostin Technology Group Co Ltd
0.120
USD
-4.01%

MYSZ
My Size Inc
1.370
USD
-0.72%

ZVSA
Zyversa Therapeutics Inc
0
USD
-76.45%

BPTH
Bio Path Holdings Inc
0
USD
-201.43%

ATXI
Avenue Therapeutics Inc
0
USD
-102.86%

SNOA
Sonoma Pharmaceuticals Inc
3.420
USD
-4.89%

NBY
NovaBay Pharmaceuticals Inc
0.672
USD
+3.22%
FAQ

What is Enveric Biosciences Inc (ENVB) stock price today?
The current price of ENVB is 1.31 USD — it has decreased -0.76 % in the last trading day.

What is Enveric Biosciences Inc (ENVB)'s business?

What is the price predicton of ENVB Stock?

What is Enveric Biosciences Inc (ENVB)'s revenue for the last quarter?

What is Enveric Biosciences Inc (ENVB)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Enveric Biosciences Inc (ENVB)'s fundamentals?

How many employees does Enveric Biosciences Inc (ENVB). have?
